ClinicalTrials.Veeva

Menu

OCT Angiography in the Glaucoma Diagnosis (OCTA)

F

Fondation Hôpital Saint-Joseph

Status

Active, not recruiting

Conditions

Glaucoma

Treatments

Diagnostic Test: Case Group
Diagnostic Test: Control Group

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Glaucoma is a chronic degenerative disease of the optic nerve. It is the second cause of blindness worldwide and a frequent cause of irreversible blindness. In 2020, epidemic health authorities have predicted about 80 million glaucoma patients. Glaucoma can be treated by topical treatment (eye drops), laser or surgery. A premature diagnosis of glaucoma is very important to prevent irreversible blindness. Pachymetry, Optical Coherence Tomography (OCT) and visual fields exams are fundamental for the development of the glaucoma diagnosis. The severity of glaucoma is defined with Hodapp-Parrish-Andersen visual field criteria. According to these criteria, glaucoma can be classified as early (with average visual field deviation, MD, of 0 to -6 dB), moderate (MD of -6 to -12 dB) and severe (MD worse than -12 dB). The progression of glaucoma is being identified by the visual fields tests, and also by the progression of alterations in the optic nerve head. The visual fields tests are long and difficult (30 minutes). It is therefore important to create additional tests and anticipate the diagnosis, in order to avoid the irreversibility of glaucoma.

Full description

The OCT Angiography (OCTA) is a non-invasive technology, marketed since 2014, that uses OCT with infrared light, with no radiation nor side effects, to evaluate within seconds the vascularization of the fundus, retina and optic nerve head, which may be useful for the glaucoma diagnosis. A recent meta-analysis has shown a decrease of the vascular density (DV) in glaucoma, so that OCTA may be useful in the advanced diagnosis of glaucoma. However, the VD values obtained were different depending on the device. In addition, no studies with the OCT Triton (Topcon®) device were considered in the analysis. The authors suggested the development of dedicated software, which would allow the evaluation of VD with different devices for a more independent and valid assessment. On the other hand, recent studies show that the diagnostic capacity of OCTA may be superior to that of OCT, and that OCTA may be more useful in determining the severity of glaucoma than OCT. It is therefore necessary to evaluate the additional diagnostic tests whether they are non-invasive and whether it allow us to give a faster diagnosis.

This study is aimed at comparing the diagnostic utility of OCTA with standard complementary glaucoma examinations (OCT and CV).

Enrollment

91 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient whose age ≥ 18 years
  • Patient consultant in the ophthalmology department of the Marie-Thérèse Health Center or the Polyclinique de la Baie
  • French speaking patient
  • Patient affiliated to a health insurance plan
  • Patient having given free, informed and express consent

Exclusion criteria

  • Patient with another ophthalmological pathology or a history of ophthalmological pathology
  • Patient with a history of ophthalmic surgery except for uncomplicated cataract surgery
  • Patient under guardianship or curatorship
  • Patient deprived of liberty
  • Pregnant or lactating woman

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

91 participants in 2 patient groups

Case Group
Experimental group
Description:
The "Case" group corresponds to patients with glaucoma following the clinical criteria for glaucoma: * papilla excavation\> 5/10 with altered ISNT rule, or neuro-retinal rhyme characteristic of glaucoma, or fiber alterations characteristic of glaucoma. * OCT with typical alterations (loss of the layer of nerve fibers or loss of these ganglion cells), loss of fibers typical of glaucoma. * Humphrey 24: 2 visual fields produced, reliable and typical of glaucoma. The assignment to the "Cas" group will be carried out by an ophthalmologist specializing in glaucoma according to the following criteria: - The intraocular pressure must be increased before the start of treatment (21 mmHg or more), except in cases of normal pressure glaucoma. The additional examination corresponds to an OCTA alone leading to an extension of the duration of the consultation by 5 minutes.
Treatment:
Diagnostic Test: Case Group
Control Groupe
Experimental group
Description:
The Control group corresponds to patients with no glaucoma, no suspicion or history of glaucoma, ocular hypertension, or alterations detected during the ophthalmological consultation. Witnesses will be matched to cases by age (+/- 5 years) and gender. For patients in this group, the additional examinations correspond to a visual field, an OCT and an OCTA leading to an extension of the duration of the consultation by 35 minutes.
Treatment:
Diagnostic Test: Control Group

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems